See more : Grizzly Discoveries Inc. (GZDIF) Income Statement Analysis – Financial Results
Complete financial analysis of Puriblood Medical Co., Ltd. (6847.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puriblood Medical Co., Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Nakanishi Inc. (7716.T) Income Statement Analysis – Financial Results
- Intellinetics, Inc. (INLX) Income Statement Analysis – Financial Results
- Gabather AB (publ) (GABA.ST) Income Statement Analysis – Financial Results
- M3-Brigade Acquisition II Corp. (MBAC-WT) Income Statement Analysis – Financial Results
- HKR International Limited (0480.HK) Income Statement Analysis – Financial Results
Puriblood Medical Co., Ltd. (6847.TWO)
About Puriblood Medical Co., Ltd.
Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In addition, the company develops P-Tex Technology, which is composed by bio-inspired molecular formula zwitterionic copolymer structure. Puriblood Medical Co., Ltd. was founded in 2016 and is based in Hsinchu City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 125.27M | 137.44M | 54.59M | 38.65M | 3.09M |
| Cost of Revenue | 118.75M | 78.78M | 48.99M | 14.27M | 3.45M |
| Gross Profit | 6.52M | 58.67M | 5.60M | 24.38M | -357.00K |
| Gross Profit Ratio | 5.21% | 42.68% | 10.26% | 63.08% | -11.54% |
| Research & Development | 25.95M | 22.44M | 20.77M | 14.70M | 12.54M |
| General & Administrative | 22.81M | 22.85M | 14.02M | 7.95M | 4.63M |
| Selling & Marketing | 8.16M | 6.14M | 6.21M | 5.03M | 3.87M |
| SG&A | 30.97M | 28.99M | 20.23M | 12.97M | 8.50M |
| Other Expenses | 0.00 | 10.57M | -1.90M | 3.11M | -21.40M |
| Operating Expenses | 56.93M | 51.43M | 40.99M | 27.67M | -21.40M |
| Cost & Expenses | 175.67M | 130.20M | 89.98M | 41.94M | -21.40M |
| Interest Income | 1.95M | 578.00K | 69.00K | 9.00K | 20.00K |
| Interest Expense | 1.36M | 1.32M | 730.00K | 1.08M | 729.00K |
| Depreciation & Amortization | 8.10M | 7.77M | 6.42M | 5.16M | 4.07M |
| EBITDA | -44.02M | 26.02M | -30.80M | 3.46M | -15.75M |
| EBITDA Ratio | -35.14% | 18.93% | -56.55% | 8.95% | -691.56% |
| Operating Income | -50.40M | 18.25M | -37.29M | -1.70M | -21.40M |
| Operating Income Ratio | -40.24% | 13.28% | -68.32% | -4.40% | -691.56% |
| Total Other Income/Expenses | -4.02M | 9.83M | -2.63M | -1.08M | 844.00K |
| Income Before Tax | -54.43M | 16.94M | -38.02M | -2.78M | -20.55M |
| Income Before Tax Ratio | -43.45% | 12.32% | -69.66% | -7.19% | -664.29% |
| Income Tax Expense | -2.83M | 405.00K | 0.00 | 0.00 | -4.07M |
| Net Income | -51.60M | 16.53M | -38.02M | -2.78M | -20.55M |
| Net Income Ratio | -41.19% | 12.03% | -69.66% | -7.19% | -664.29% |
| EPS | -3.63 | 1.16 | -3.26 | -0.32 | -2.39 |
| EPS Diluted | -3.63 | 1.16 | -3.26 | -0.32 | -2.39 |
| Weighted Avg Shares Out | 14.23M | 14.23M | 11.65M | 8.68M | 8.60M |
| Weighted Avg Shares Out (Dil) | 14.23M | 14.23M | 11.65M | 8.68M | 8.60M |
Source: https://incomestatements.info
Category: Stock Reports